These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15110235)

  • 1. Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin.
    Aukrust P; Yndestad A; Damås JK; Gullestad L
    Autoimmun Rev; 2004 Mar; 3(3):221-7. PubMed ID: 15110235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets.
    Gullestad L; Aukrust P
    Heart Fail Monit; 2001; 2(1):8-13. PubMed ID: 12634893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches.
    Gullestad L; Aukrust P
    Am J Cardiol; 2005 Jun; 95(11A):17C-23C; discussion 38C-40C. PubMed ID: 15925560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulating therapy: new treatment modality in congestive heart failure.
    Aukrust P; Damås JK; Gullestad L
    Congest Heart Fail; 2003; 9(2):64-9. PubMed ID: 12671336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of anticytokine therapy in congestive heart failure.
    Aukrust P; Yndestad A; Damås JK; Gullestad L
    Am J Cardiovasc Drugs; 2004; 4(3):169-77. PubMed ID: 15134469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proinflammatory cytokines in cardiovascular diseases as potential therapeutic target].
    Bielecka-Dabrowa A; Wierzbicka M; Goch JH
    Wiad Lek; 2007; 60(9-10):433-8. PubMed ID: 18350717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory trials in chronic heart failure.
    Aukrust P; Yndestad A; Ueland T; Damås JK; Gullestad L
    Heart Fail Monit; 2006; 5(1):2-9. PubMed ID: 16547529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune activation in chronic heart failure.
    Torre-Amione G
    Am J Cardiol; 2005 Jun; 95(11A):3C-8C; discussion 38C-40C. PubMed ID: 15925558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of intravenous immunoglobulin in the treatment of chronic heart failure.
    Aukrust P; Yndestad A; Ueland T; Damås JK; Frøland SS; Gullestad L
    Int J Cardiol; 2006 Sep; 112(1):40-5. PubMed ID: 16893578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches.
    Gong KZ; Song G; Spiers JP; Kelso EJ; Zhang ZG
    Int J Clin Pract; 2007 Apr; 61(4):611-21. PubMed ID: 17394435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin].
    Gullestad L; Aass H; Andreassen AK; Ihlen H; Simonsen S; Kjekshus J; Wikeby L; Nitter-Hauge S; Fjeld JG; Lien E; Ueland T; Frøland SS; Aukrust P
    Tidsskr Nor Laegeforen; 2001 Jun; 121(16):1902-7. PubMed ID: 11488180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure.
    Gong K; Zhang Z; Sun X; Zhang X; Li A; Yan J; Luo Q; Gao Y; Feng Y
    Am Heart J; 2006 Jan; 151(1):62-8. PubMed ID: 16368293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications.
    Aukrust P; Gullestad L; Ueland T; Damås JK; Yndestad A
    Ann Med; 2005; 37(2):74-85. PubMed ID: 16026115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Device-based nonspecific immunomodulation therapy (Celacade), and its potential role in the treatment of chronic heart failure.
    Sporter RJ; Kim JH; Frishman WH
    Cardiol Rev; 2008; 16(6):280-7. PubMed ID: 18923231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers.
    George J; Patal S; Wexler D; Abashidze A; Shmilovich H; Barak T; Sheps D; Keren G
    Arch Intern Med; 2005 Jun; 165(11):1304-9. PubMed ID: 15956012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure.
    Gullestad L; Aass H; Fjeld JG; Wikeby L; Andreassen AK; Ihlen H; Simonsen S; Kjekshus J; Nitter-Hauge S; Ueland T; Lien E; Frøland SS; Aukrust P
    Circulation; 2001 Jan; 103(2):220-5. PubMed ID: 11208680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of inflammation in heart failure].
    Fuchs M; Drexler H
    Herz; 2004 Dec; 29(8):782-7. PubMed ID: 15599675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?
    Celis R; Torre-Martinez G; Torre-Amione G
    Curr Opin Cardiol; 2008 May; 23(3):254-60. PubMed ID: 18382215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.